Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 8/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 2/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5744911 | 1.00 | TACR1 (0.40) | TACR1DRD2DRD4L3MBTL1OPRL1 | |
| SCHEMBL6397078 | 0.91 | OPRL1 (0.39) | TACR1DRD2DRD4OPRL1KCNH2 | |
| SCHEMBL6397081 | 0.91 | OPRL1 (0.39) | TACR1DRD2DRD4OPRL1KCNH2 | |
| SCHEMBL6309911 | 0.91 | TACR1 (0.41) | TACR1DRD2DRD4OPRL1KCNH2 | |
| SCHEMBL6394116 | 0.91 | TACR1 (0.41) | TACR1DRD2DRD4OPRL1KCNH2 | |
| SCHEMBL6311587 | 0.91 | TACR1 (0.41) | TACR1DRD2DRD4OPRL1KCNH2 | |
| SCHEMBL6309919 | 0.91 | TACR1 (0.41) | TACR1DRD2DRD4OPRL1KCNH2 | |
| SCHEMBL6311590 | 0.91 | TACR1 (0.41) | TACR1DRD2DRD4OPRL1KCNH2 | |
| SCHEMBL6397911 | 0.90 | TACR1 (0.41) | TACR1DRD2DRD4OPRL1KCNH2 | |
| SCHEMBL6318088 | 0.89 | KCNH2 (0.41) | TACR1DRD2DRD4OPRL1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043354-A1 | NK1 antagonist | PFIZER INC | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043354-A1 | NK1 antagonist | TACR2, TACR1, TAC3 | TACR1 2/4885DRD2 701/4885DRD4 1289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.